Opiate abuse is a significant risk factor for HIV-1 infection and several studies have shown that, in combination, opiates and HIV-1 lead to significantly greater damage to the brain. Thus, a new combinatory strategy is needed to impede HIV-1 infection and mitigate opiate effects on the CNS. In spite of significant advances in anti-retroviral therapy (ART), the elimination of HIV-1 CNS reservoirs remains a formidable task. This is mainly attributed to the integration of the HIV-1 proviral DNA into the host genome causing viral latency in the reservoirs, including the brain. Further, the inability of ART to penetrate the BBB after systemic administration makes the brain one of the dominant HIV reservoirs. Thus, elimination of HIV-1 from the brain remains a clinically daunting and key task in the cure of HIV-1/opioid CNS disease. Most recently, we (Dr. Khalili's lab at Temple University) developed an RNA directed gene-editing strategy using Cas9/gRNA that successfully eliminates entire integrated copies of the HIV-1 genome from the host chromosome. However, delivery of this powerful Cas9/gRNA complex across the BBB is limited and an effective method for delivery and release of Cas9/gRNA is critically required to eliminate the HIV reservoir in the brain. Our laboratory (Dr. Nair's team at Florida International University) has recently patented (US patent: US20130317279 A1 and WO patent: PCT/US2013/068698) technology involving novel magneto-electro nanoparticle (MENP) based drug delivery system, which offers capability of on-demand drug release across the BBB. The collaboration of these two laboratories provided preliminary evidence that Cas9/gRNA binds to MENP, navigated across the BBB by magnetic force, and on-demand release of functionally active Cas9/gRNA by external AC stimulation. We provide evidence that morphine induced activation of HIV infection could be mitigated by methylnaltrexone (MTNX) ( receptor antagonist). In this multi-PI application we hypothesize that efficient nanoformulations (NFs) containing Cas9/gRNA and MTNX can serve as an effective carrier to deliver Cas9/gRNA targeting HIV-1 across the BBB for the recognition and complete eradication of the HIV reservoir in brain and to treat/prevent neurological deficits observed in morphine-using HIV infected subjects. To test our hypothesis, we propose to refine our design method, and develop, characterize, and evaluate the delivery and on-demand release of Cas9/gRNA using an in vitro BBB-HIV infection model (Aim #1). Next, we will evaluate and pre-screen the in vivo efficacy of the developed NFs in excising integrated copies of HIV DNA in Tg26 transgenic mice harboring the entire viral genome (Aim #2).
In Aim #3 we will develop and use BLT mouse model to validate and assess the in vivo efficacy of the MENP-Cas9/gRNA NFs to recognize and eradicate latently infected HIV-1 reservoirs. Finally, in Aim #4 we will examine the in vivo efficacy of the most pre-screened NFs in a BLT morphine mouse model to assess the potential excision of HIV-1 proviral DNA and morphine induced reactivation of latent HIV infection and to reverse neurological deficits by NFs containing MNTX.

Public Health Relevance

Morphine has been shown to complicate the severity of HIV-1 and its progression in the brain. The current antiviral therapy has failed to eradicate the HIV-1 genome and alleviate the complications caused by morphine and HIV-1 in the CNS. Our new strategy, which efficiently eliminates the HIV-1 genome from the infected cells along with the use of a robust delivery system such as nanoparticles, offers a new avenue for developing a method for eradication of HIV-1 and a cure for neuroAIDS.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Pollock, Jonathan D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Florida International University
Schools of Medicine
United States
Zip Code
Vashist, Arti; Kaushik, Ajeet; Vashist, Atul et al. (2018) Nanogels as potential drug nanocarriers for CNS drug delivery. Drug Discov Today 23:1436-1443
Mohseni Ahooyi, Taha; Shekarabi, Masoud; Torkzaban, Bahareh et al. (2018) Dysregulation of Neuronal Cholesterol Homeostasis upon Exposure to HIV-1 Tat and Cocaine Revealed by RNA-Sequencing. Sci Rep 8:16300
Vashist, Arti; Kaushik, Ajeet; Vashist, Atul et al. (2018) Advances in Carbon Nanotubes-Hydrogel Hybrids in Nanomedicine for Therapeutics. Adv Healthc Mater 7:e1701213
Jayant, Rahul Dev; Tiwari, Sneham; Atluri, Venkata et al. (2018) Multifunctional Nanotherapeutics for the Treatment of neuroAIDS in Drug Abusers. Sci Rep 8:12991
Kaushik, Ajeet; Jayant, Rahul Dev; Bhardwaj, Vinay et al. (2018) Personalized nanomedicine for CNS diseases. Drug Discov Today 23:1007-1015
Jayant, Rahul Dev; Atluri, Venkata S R; Tiwari, Sneham et al. (2017) Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS. J Neurovirol 23:603-614
Kaushik, Ajeet; Tiwari, Sneham; Jayant, Rahul D et al. (2017) Electrochemical Biosensors for Early Stage Zika Diagnostics. Trends Biotechnol 35:308-317
Vashist, Arti; Kaushik, Ajeet; Alexis, Kayla et al. (2017) Bioresponsive Injectable Hydrogels for On-demand Drug Release and Tissue Engineering. Curr Pharm Des 23:3595-3602
Kaushik, Ajeet; Nikkhah-Moshaie, Roozbeh; Sinha, Raju et al. (2017) Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells. Sci Rep 7:45663
Jayant, Rahul Dev; Sosa, Daniela; Kaushik, Ajeet et al. (2016) Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv 13:1433-45

Showing the most recent 10 out of 12 publications